The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02129179

Enrollment

Registered

2014-05-02

Start date

2014-06-30

Completion date

2016-12-31

Last updated

2018-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.

Interventions

DRUGGlucagon-Like Peptide 1

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age over 18 * Able to give informed consent * On the waiting list for heart transplant * Left Ventricular Dysfunction awaiting catheterisation

Exclusion criteria

* Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1 receptor agonist or insulin * Women of child bearing age and breast feeding women * Cardiac pacemaker or other implanted metallic device * Unable to give informed consent

Design outcomes

Primary

Measure	Time frame
Change in Pulmonary Vascular Resistance with Glucagon-Like Peptide-1	30 minutes

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026